Clinical Trial Update: Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating liposomal cytarabine for central nervous system resistant or relapsed acute lymphoblastic leukemia in children.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Liposomal cytarabine (cytarabine liposome)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Acute Lymphoblastic Leukemia | Phase 2 | Status: UNKNOWN